North America Monoclonal Antibodies Therapeutics Market size was valued at USD 47,061.46 million in 2018, reached USD 93,933.37 million in 2024, and is anticipated to reach USD 247,621.77 million by 2032, growing at a CAGR of 12.6% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
North America Monoclonal Antibodies Therapeutics Market Size 2024
USD 93,933.37 million
North America Monoclonal Antibodies Therapeutics Market, CAGR
12.6%
North America Monoclonal Antibodies Therapeutics Market Size 2032
USD 247,621.77 million
The North America Monoclonal Antibodies Therapeutics Market is dominated by leading players such as F. Hoffmann-La Roche Ltd, Sanofi, AbbVie Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services, Inc. These companies maintain strong market positions through extensive product portfolios, strategic collaborations, and continuous innovation in therapeutic development. The United States leads the regional market with a 74% share, driven by advanced healthcare infrastructure, high research funding, and a strong presence of biopharmaceutical firms. Canada and Mexico follow, contributing significantly to regional growth through expanding clinical trials and increased biologics adoption.
Market Insights
North America Monoclonal Antibodies Therapeutics Market size was valued at USD 93,933.37 million in 2024 and is projected to reach USD 247,621.77 million by 2032, growing at a CAGR of 12.6%. Humanized monoclonal antibodies (mAbs) held the largest source segment share of 62%, while oncology led the therapeutic area with 48%, and intravenous administration dominated with 71% share.
The market growth is primarily driven by the rising prevalence of chronic and autoimmune diseases, increasing cancer incidence, and growing demand for targeted therapies with higher efficacy and reduced side effects.
A major trend shaping the market is the expansion of subcutaneous (SC) delivery systems, offering patient-friendly administration and supporting home-based treatment models. Integration of AI and data analytics in drug development is also accelerating precision medicine adoption.
The market is highly competitive, led by F. Hoffmann-La Roche Ltd, Sanofi, AbbVie Inc., and other key players, focusing on innovation, strategic collaborations, and pipeline expansion.
High manufacturing costs, complex production processes, and stringent regulatory requirements remain key restraints, while the United States leads the regional market with 74% share, followed by Canada at 16% and Mexico at 10%.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
In the North America Monoclonal Antibodies Therapeutics Market, humanized monoclonal antibodies (mAbs) dominate the source segment, capturing 62% of the total market share in 2024. Their high biocompatibility, reduced immunogenicity, and enhanced efficacy in treating complex diseases such as cancer and autoimmune disorders have positioned them as the preferred choice among healthcare providers. The segment’s growth is further propelled by the increasing adoption of advanced antibody engineering technologies and the growing number of FDA approvals for humanized mAb therapies targeting oncology and chronic inflammatory conditions.
For instance, in 2024, Roche’s PiaSky® (crovalimab-akkz), a humanized IgG1 monoclonal antibody, received full FDA approval for treating paroxysmal nocturnal hemoglobinuria (PNH) with engineered features to improve recycling and reduce immune reactions.
By Therapeutic Area:
The oncology segment leads the North America Monoclonal Antibodies Therapeutics Market, accounting for 48% of the total market share in 2024. The dominance of this segment is driven by the rising prevalence of various cancers, the availability of targeted therapies, and increased R&D investments by pharmaceutical companies. Additionally, the growing number of clinical trials focused on tumor-specific antigens and the integration of monoclonal antibodies with immunotherapy approaches continue to expand their therapeutic applications, reinforcing oncology’s leading position across the region.
For instance, Roche received FDA approval in 2024 for Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor providing faster cancer immunotherapy administration for lung, liver, skin, and soft tissue cancers.
By Route of Administration:
The intravenous (IV) route of administration remains the dominant mode in the North America Monoclonal Antibodies Therapeutics Market, holding about 71% of the total market share in 2024. This preference is attributed to its rapid bioavailability, controlled dosage administration, and suitability for complex or high-dose antibody formulations. Hospitals and specialty clinics primarily administer IV therapies for cancer, autoimmune, and infectious diseases, ensuring precise delivery and efficacy. However, the subcutaneous (SC) route is gaining traction due to its patient-friendly nature and growing shift toward home-based treatment models.
Key Growth Drivers
Rising Prevalence of Chronic and Autoimmune Diseases
The growing incidence of chronic and autoimmune disorders such as rheumatoid arthritis, multiple sclerosis, and various cancers is a major driver of the North America Monoclonal Antibodies Therapeutics Market. An aging population and changing lifestyle patterns have led to a surge in disease cases, increasing demand for effective targeted therapies. Monoclonal antibodies offer superior specificity and fewer side effects compared to traditional treatments, making them the preferred therapeutic option. This rising disease burden continues to fuel demand and encourage research into novel antibody-based treatments.
For instancer, Genentech’s Atezolizumab (Tecentriq) received FDA approval in 2021 as adjuvant treatment for non-small cell lung cancer, where it improved disease-free survival compared to placebo in patients with PD-L1-positive tumors, reducing the risk of disease recurrence or death by 36% in pivotal trials.
Advancements in Antibody Engineering and Biologic Research
Technological progress in antibody engineering, hybridoma, and recombinant DNA methods has significantly improved the safety and efficacy of monoclonal antibodies. These advancements have led to the creation of fully human and humanized antibodies with enhanced stability and extended half-lives. North America’s strong biopharmaceutical research infrastructure, supported by academic partnerships and government funding, further accelerates innovation. Continuous improvements in biologic design and manufacturing processes are broadening therapeutic applications, contributing to the market’s sustained growth and competitive edge in global antibody development.
For instance, hybridoma technology, introduced in 1975 by Köhler and Milstein, remains foundational for producing highly specific monoclonal antibodies by fusing B cells with myeloma cells to create immortal hybridoma lines capable of continuous antibody production.
Growing FDA Approvals and Strategic Collaborations
The increasing number of FDA approvals for monoclonal antibody therapies across oncology, infectious diseases, and autoimmune disorders strengthens market expansion. Regulatory incentives such as orphan drug status and breakthrough therapy designations encourage rapid commercialization. Moreover, strategic collaborations between major pharmaceutical and biotech companies are enhancing R&D capabilities and expanding clinical pipelines. These partnerships enable cost efficiency, technological innovation, and broader treatment accessibility, positioning North America as a leader in antibody-based therapeutics and driving steady market advancement.
Key Trends and Opportunities
Expansion of Subcutaneous Delivery Systems
A major trend shaping the market is the growing shift toward subcutaneous (SC) delivery systems. Patients and healthcare providers increasingly favor SC administration for its convenience, shorter infusion times, and compatibility with home-based treatments. Pharmaceutical firms are developing advanced SC formulations that maintain efficacy while improving patient comfort and compliance. This transition from intravenous to subcutaneous delivery not only enhances patient experience but also reduces hospital dependency and overall treatment costs, reinforcing the adoption of antibody therapies across North America.
For instance, Alphamab Oncology developed a proprietary platform for high-concentration subcutaneous formulations, successfully producing KN035, the world’s first subcutaneously injectable PD-(L)1 inhibitor that enhances patient compliance by allowing smaller injection volumes while preserving drug stability.
Integration of AI and Data Analytics in Drug Development
The integration of artificial intelligence (AI) and data analytics presents significant opportunities in monoclonal antibody discovery and optimization. AI-driven models enable faster identification of antigen targets, molecular design, and prediction of therapeutic efficacy. Leading pharmaceutical companies are leveraging machine learning algorithms to streamline clinical trial design and enhance precision medicine approaches. This technology-driven evolution reduces R&D costs and accelerates time-to-market, opening avenues for developing next-generation antibody therapies tailored to patient-specific needs and rare disease conditions.
For instance, MAbSilico has developed an in silico pipeline that designs humanized antibody sequences optimized for affinity and developability within days, significantly de-risking and speeding up the discovery process.
Key Challenges
High Manufacturing Costs and Complex Production Processes
The manufacturing of monoclonal antibodies involves sophisticated bioprocessing, stringent regulatory oversight, and expensive raw materials, leading to high production costs. These expenses often translate into elevated therapy prices, limiting affordability and accessibility. Additionally, maintaining consistency and scalability during production remains a technical challenge for many biopharmaceutical firms. To address this, companies are investing in single-use bioreactors, continuous bioprocessing, and automation technologies, though cost pressures continue to constrain market growth, especially in smaller healthcare settings.
Stringent Regulatory Requirements and Approval Delays
The North American regulatory landscape for monoclonal antibodies is highly demanding, requiring extensive preclinical testing, long clinical trial phases, and comprehensive post-market surveillance. These rigorous processes often delay product approvals and increase development costs, creating hurdles for smaller biotech firms. The evolving guidelines for biosimilars add further complexity, necessitating additional validation and documentation. While regulatory bodies such as the FDA are working to expedite reviews for critical therapies, the lengthy approval timelines remain a key challenge affecting market entry and innovation speed.
Regional Analysis
United States
The United States holds the largest share of the North America Monoclonal Antibodies Therapeutics Market, accounting for 74% of the regional revenue in 2024. The dominance of the U.S. market is supported by advanced healthcare infrastructure, high R&D investments, and the strong presence of leading biopharmaceutical companies such as Amgen, AbbVie, and Bristol Myers Squibb. Robust FDA approval processes and continuous innovation in antibody engineering technologies have accelerated the development of novel therapeutic antibodies. Increasing prevalence of cancer, autoimmune diseases, and favorable reimbursement policies continue to strengthen the market’s growth trajectory across the country.
Canada
Canada represents 16% of the North America Monoclonal Antibodies Therapeutics Market in 2024, driven by rising healthcare expenditure and growing adoption of biologic therapies. The country’s focus on improving patient access to innovative biologics and biosimilars has encouraged strong demand in oncology and autoimmune disease segments. Collaborative research initiatives between academic institutions and biopharmaceutical companies are expanding clinical development pipelines. Moreover, supportive regulatory frameworks from Health Canada and public funding for advanced therapeutics contribute to the country’s growing share, making Canada a key emerging hub for monoclonal antibody research and commercialization.
Mexico
Mexico accounts for 10% of the North America Monoclonal Antibodies Therapeutics Market in 2024, with increasing government initiatives to enhance healthcare accessibility and expand biologics availability. The country’s market growth is fueled by rising incidences of chronic diseases and the gradual integration of advanced biologic therapies in public and private healthcare sectors. Expanding partnerships with global pharmaceutical companies and improved infrastructure for clinical trials are fostering greater adoption of monoclonal antibody-based treatments. Although regulatory challenges and cost constraints persist, Mexico’s improving healthcare landscape positions it as a growing contributor to the regional market.
Market Segmentations:
By Sources
Humanized mAbs
Chimeric mAbs
Others
By Therapeutic Area
Oncology
Autoimmune & Inflammatory Diseases
Infectious Diseases
Cardiovascular & Metabolic Disorders
Neurological Disorders
Others
By Route of Administration
Subcutaneous (SC)
Intravenous (IV)
Others
By Sales Channel
Hospital Pharmacies
Specialty Clinics
Retail Pharmacies
Online Pharmacies
By Region
US.
Canada
Mexico
Competitive Landscape
The competitive landscape of the North America Monoclonal Antibodies Therapeutics Market is defined by the strong presence of major players such as F. Hoffmann-La Roche Ltd, Sanofi, AbbVie Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Johnson & Johnson Services, Inc. These companies dominate the regional market through extensive product portfolios, robust R&D investments, and continuous innovation in antibody development. Strategic collaborations, mergers, and acquisitions are central to strengthening their market position and expanding therapeutic pipelines. The focus remains on developing next-generation antibodies with enhanced efficacy, lower immunogenicity, and improved delivery systems. In addition, many key players are leveraging advanced technologies such as AI-driven drug discovery and hybridoma engineering to accelerate production and reduce development costs. With increasing FDA approvals and expansion of biosimilar portfolios, competition continues to intensify, driving innovation and accessibility across the regional therapeutic landscape.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In January 8, 2024, Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology platform for next-generation antibody drug conjugates, in an all-cash deal valued at approximately $2.0 billion.
In February 28, 2024, AbbVie and OSE Immunotherapeutics announced a global license and collaboration agreement to develop OSE-230, a monoclonal antibody in pre-clinical stages targeting chronic and severe inflammation.
In October 17, 2025, Rani Therapeutics signed a major licensing agreement with Chugai Pharmaceutical to develop and commercialize an oral version of Chugai’s experimental antibody for a rare disease, with the deal potentially expanding to five additional drugs, totaling up to $1.09 billion.
In 2024, AbbVie announced the acquisition of Aliada Therapeutics, a company specializing in developing ALIA-1758, an anti-pyroglutamate amyloid beta monoclonal antibody aimed at treating Alzheimer’s disease.
Report Coverage
The research report offers an in-depth analysis based on Sources, Therapeutic Area, Route of Administration, Sales Channeland Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The market will continue to expand with increasing adoption of targeted monoclonal antibody therapies across oncology and autoimmune diseases.
Advancements in antibody engineering and biomanufacturing technologies will enhance therapeutic precision and reduce production complexity.
The growing approval of biosimilar monoclonal antibodies will increase treatment accessibility and affordability across the region.
Strategic partnerships between pharmaceutical companies and research institutions will accelerate innovation and clinical trial development.
Rising investment in personalized medicine will drive demand for monoclonal antibodies tailored to individual patient profiles.
Subcutaneous delivery formulations will gain momentum due to their convenience and patient compliance advantages.
Expansion of AI-driven drug discovery platforms will improve efficiency in antibody design and reduce development timelines.
Healthcare digitization and real-world data analytics will strengthen post-market surveillance and treatment optimization.
Increasing government support for biologics research will encourage domestic production and reduce dependency on imports.
Continued emphasis on oncology and chronic disease management will sustain market growth and therapeutic diversification.
11.1. Monoclonal Antibodies Therapeutics Market Overview By Sales Channel Segment
11.1.1. Monoclonal Antibodies Therapeutics Market Revenue Share By Sales Channel
11.2. Hospital Pharmacies
11.3. Specialty Clinics
11.4. Retail Pharmacies
11.5. Online Pharmacies
CHAPTER NO. 12 : NORTH AMERICA MONOCLONAL ANTIBODIES THERAPEUTICS MARKET – COUNTRY ANALYSIS
12.1. North America Monoclonal Antibodies Therapeutics Market Overview By Country Segment
12.1.1. North America Monoclonal Antibodies Therapeutics Market Revenue Share By Region
12.2. North America
12.2.1. North America Monoclonal Antibodies Therapeutics Market Revenue By Country
12.2.2. Sources
12.2.3. North America Monoclonal Antibodies Therapeutics Market Revenue By Sources
12.2.4. Therapeutic Area
12.2.5. North America Monoclonal Antibodies Therapeutics Market Revenue By Therapeutic Area
12.2.6. Route of Administration
12.2.7. North America Monoclonal Antibodies Therapeutics Market Revenue By Route of Administration
12.2.8. Sales Channel
12.2.9. North America Monoclonal Antibodies Therapeutics Market Revenue By Sales Channel
12.3. U.S.
12.4. Canada
12.5. Mexico
CHAPTER NO. 13 : COMPANY PROFILES
13.1. F. Hoffmann-La Roche Ltd
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Financial Overview
13.1.4. Recent Developments
13.1.5. Growth Strategy
13.1.6. SWOT Analysis
13.2. Sanofi
13.3. Abbvie Inc.
13.4. Bristol Myers Squibb Company
13.5. Novartis AG
13.6. AstraZeneca
13.7. Amgen Inc.
13.8. Eli Lilly and Company
13.9. Takeda Pharmaceutical Company Limited
13.10. Johnson & Johnson Services, Inc.
13.11. Other Key Players
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for the North America Monoclonal Antibodies Therapeutics Market, and what is its projected size in 2032?
The North America Monoclonal Antibodies Therapeutics Market was valued at USD 93,933.37 million in 2024 and is projected to reach USD 247,621.77 million by 2032.
At what Compound Annual Growth Rate is the North America Monoclonal Antibodies Therapeutics Market projected to grow between 2025 and 2032?
What are the primary factors fueling the growth of the North America Monoclonal Antibodies Therapeutics Market?
Key growth drivers include the rising prevalence of chronic and autoimmune diseases, advancements in antibody engineering, and increasing FDA approvals for novel therapies.
Who are the leading companies in the North America Monoclonal Antibodies Therapeutics Market?
Major companies include F. Hoffmann-La Roche Ltd, Sanofi, AbbVie Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca, and Amgen Inc.
Which region commanded the largest share of the North America Monoclonal Antibodies Therapeutics Market in 2024?
The United States commanded the largest share of 74% in the North America Monoclonal Antibodies Therapeutics Market in 2024.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Italy Monoclonal Antibodies Therapeutics Market size was valued at USD 1,559.95 Million in 2018 and grew to USD 3,178.37 Million in 2024. It is anticipated to reach USD 8,611.32 Million by 2032, growing at a CAGR of 13.2% during the forecast period
Germany Monoclonal Antibodies Therapeutics Market size was valued at USD 8,695.57 million in 2018, growing to USD 16,903.06 million in 2024, and is anticipated to reach USD 42,949.36 million by 2032, at a CAGR of 12.4% during the forecast period.
France Monoclonal Antibodies Therapeutics Market was valued at USD 4,954.86 million in 2018 and reached USD 10,293.72 million in 2024. It is projected to grow further, reaching USD 28,582.89 million by 2032, registering a CAGR of 13.6% during the forecast period.
Europe Monoclonal Antibodies Therapeutics Market size was valued at USD 35,091.08 million in 2018, grew to USD 70,504.95 million in 2024, and is anticipated to reach USD 187,551.80 million by 2032, at a CAGR of 12.9% during the forecast period.
Australia Monoclonal Antibodies Therapeutics Market size was valued at USD 1,948.81 million in 2018, is expected to reach USD 4,190.72 million in 2024, and is anticipated to reach USD 12,173.18 million by 2032, growing at a CAGR of 14.1% during the forecast period.
The Gaucher Disease Drugs market was valued at USD 1.71 billion in 2024 and is projected to reach USD 2.01 billion by 2032, growing at a CAGR of 2.1% during the forecast period.
Specimen Validity Testing Market size was valued USD 2.2 billion in 2024 and is anticipated to reach USD 3.58 billion by 2032, at a CAGR of 6.29% during the forecast period.
The Robotic Radiotherapy market was valued at USD 1.24 billion in 2024 and is projected to reach USD 3.01 billion by 2032, growing at a CAGR of 11.76% during the forecast period.
The Healthcare Smart Card Reader Market was valued at USD 1.59 billion in 2024 and is projected to reach USD 4.32 billion by 2032, growing at a CAGR of 13.3% during the forecast period.
The Doxorubicin market was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.6 billion by 2032, growing at a CAGR of 4.7% during the forecast period.
The glucagon market size was valued at USD 409.75 million in 2024 and is anticipated to reach USD 607.36 million by 2032, growing at a CAGR of 5.3% during the forecast period.
Monoclonal Antibodies Therapeutics Market size was valued at USD 122,396.5 Million in 2018 and USD 248,032.3 Million in 2024, and is anticipated to reach USD 667,444.1 Million by 2032, at a CAGR of 13.29% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$2999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
